Fosun Pharma returns to onshore debt market

Hong Kong- and Shanghai-listed group hopes to take advantage of new liquidity flowing through the system.

Fosun Pharma returns to onshore debt market

Shanghai Fosun Pharmaceutical Group begins bookbuilding for an Rmb3 billion $471 million domestic bond issue on Wednesday, hoping to take advantage of new liquidity flooding into the financial system following the central’s bank surprise cut to banks’ reserve requirement ratio RRR on Monday.

The medical products manufacturer, controlled by mainland billionaire Guo Guangchang, is returning to the domestic bond market for the first time since September when it issued Rmb400 million off its...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: fosun | guo guangchang | bonds | ubs | haitong | tebon

Print Edition

FinanceAsia Print Edition

EVENTS